BrightPath Biotherapeutics Co., Ltd.

4594

JP3274140007

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 11:52:59 2024-04-30 pm EDT			5-day change	1st Jan Change
61 ^JPY	+1.67%		+5.17%	-29.89%

2023	BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	CI
2023	BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	CI

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm

February 31, 2022

On February 1, 2022, BrightPath Biotherapeutics Co., Ltd. closed the transaction.

Latest news about BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	Nov. 29	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	Nov. 13	CI
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	22-09-19	CI
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	22-04-13	MT
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	22-04-13	MT
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	22-04-12	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	22-01-31	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	22-01-13	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	20-04-22	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	20-04-06	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	18-11-09	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	18-08-10	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	18-05-11	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	18-02-14	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	17-12-07	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	17-11-21	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	17-11-10	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-08-14	CI
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo	17-07-23	CI
GreenPeptide Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-05-12	CI
GreenPeptide Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2016, Provides Earnings Guidance for the Year Ending March 31, 2017	17-02-10	CI
GreenPeptide Co., Ltd. Announces Notice of Initiation of Phase II Clinical Trial of GRN-1201	17-01-27	CI
Advanced Immunotherapy Co., Ltd. announced that it has received funding from GreenPeptide Co., Ltd.	16-11-30	CI
Advanced Immunotherapy Co., Ltd. announced that it expects to receive funding from GreenPeptide Co., Ltd.	16-11-19	CI
GreenPeptide Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending March 31, 2017	16-11-11	CI

Chart BrightPath Biotherapeutics Co., Ltd.

Duration

Period

Chart BrightPath Biotherapeutics Co., Ltd.

More charts

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHTPATH BIOTHERAPEUTICS CO., LTD.	-29.89%	26.64M
IQVIA HOLDINGS INC.	+0.17%	42.86B
MODERNA, INC.	+10.92%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.23%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.63B
MEDPACE HOLDINGS, INC.	+26.69%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.92B
UNITED THERAPEUTICS CORPORATION	+6.57%	11.21B

Other Biotechnology & Medical Research